Hepatitis B Information
Hepatitis B is one of the range of viral diseases which affect the liver and it can cause long term morbidity as well as mortality in certain patients. Estimates suggest that over two billion people throughout the world are currently infected or have been at some stage during their life. Contact with body fluids such as through contaminated needle-stick injury or via perinatal contact from mother to child account for the main risk of transmission. The virus has been isolated from semen, vaginal fluid, tears and saliva. Even though the virus has been isolated from various blood-sucking arthropods (eg mosquitoes & bedbugs) there is no evidence of multiplication of the virus in these insects. Direct transmission can occur and care should especially be taken when squashing any of these insects in a high-risk part of the world.
It has been estimated that Hepatitis B is about 100 time more infective than the human immunodeficiency virus (HIV).
Generally most patients who become infected show an incubation period of between two to six months.
In the prodromal stage patients usually develop fever, a flu-like illness, joint aches and a loss of appetite. Headache can also be a pronounced symptom and occasionally patients show a skin rash. Jaundice develops at this stage accompanied by dark urine and a pale stool. In the majority of cases recovery starts after about three to four weeks. The itchy skin reaction and constitutional changes with Hepatitis B may be significantly less than those experienced with Hepatitis A.
The prodromal symptoms can be easily confused for other viral diseases such as ‘flu and mononucleosis. The tenderness in the liver region may lead to consideration of hepatic Amoebiasis or Typhoid. Once jaundice appears conditions such as lobar pneumonia and malaria become possibilities. The differential from hepatitis A may depend on serological testing though the incubation period usually differs significantly.
The majority of cases will resolve over a few months though a number of those infected may develop into long term carriers who are capable of transmitting the disease to others.
About 2% to 10% of adults infected by Hepatitis B progress to become chronic carriers with Hepatitis B surface antigen (HBsAg) persisting in their serum for longer than six months. These patients have a long-term risk of developing some of the more significant complications from this disease including Cirrhosis and Liver Cancer. Children have a much higher risk of becoming carriers and in those infected at birth this level rises to a staggering 90%. Most carriers are, as excepted, asymptomatic though some do present with non-specific lethargy and malaise.
Numerous attempts have been made to treat this viral disease with agents such as Interferon and Aednine arabinoside. Trials are still on-going and a number of other agents are being tested but in the majority of the world, where this disease is most prevalent, these agents are unavailable. Generally supportive therapy is used as the sole line of therapy.
The World Health Organisation has set a target of 2010 for the eradication of the disease throughout the world. Whether or not this is achievable depends greatly on the motivation of individual countries to instigate a control programme with active vaccination. Those exposed to the virus can be given urgent passive protection with Hepatitis B Immunoglobulin (HBIG) but in the majority of cases the best hope for control is through the use of active vaccination programmes. Cost is a significant factor in this debate and so far very few of the European countries have even introduced the vaccine into their normal childhood programme.
Current Vaccines in Ireland:
Over the past number of years a genetically engineered Hepatitis B vaccine has been available. This vaccine is given on three occasions over a six month period and it is estimated that between 80% to 90% of adults seroconvert and are provided with very adequate protection.